Briefly quite active in SBIR (2006) - formerly known as PlasmaTech Biopharmaceuticals Inc and a Access Pharmaceuticals - Abeona Therapeutics was originally trading on AMEX. Following delisting, the firm moved to OTC. The firm then issued another IPO on NASDAQ in December 2014. Now located in New York, NY, the firm has also a presence in Cleveland, OH and in Madrid, Spain. With technologies licensed from the Universities of Minnnesota, Nebraska and North Carolina, Abeona Therapeutics is focused on developing and delivering gene therapy and plasma-based products for severe and life-threatening rare diseases. Lead programs are adeno-associated virus (AAV)-based gene therapies for Sanfilippo syndrome (MPS IIIB and IIIA) in collaboration with patient advocate groups, researchers, and clinicians. The company is also developing gene therapy for juvenile Batten disease (JBD); and for Fanconi anemia (FA) disorder using a CRISPR/Cas9-based gene editing approach to gene therapy program for rare blood diseases. In addition, it is developing rare plasma protein therapies, including SDF AlphaT (alpha-1 protease inhibitor) for inherited COPD using its proprietary Salt Diafiltration (SDFT) ethanol-free process. The company is involved in marketing MuGard, a mucoadhesive oral wound rinse for mucositis, stomatitis, aphthous ulcers, and traumatic ulcers; and ProctiGard, a mucoadhesive oral wound rinse for the treatment of rectal mucositis and radiation proctitis.